Novo’s Ozempic Pill Fails in Long-Shot Alzheimer’s Effort

A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk studies that aimed to open up a new use for blockbuster obesity drugs. Patients who took the medicine didn’t see their disease progress more slowly based on a cognitive assessment, the Danish drugmaker said Monday. Novo will discontinue a planned one-year extension of the studies. The stock plunged as much as 12.4% in Copenhagen, hitting the lowest level since July 2021.Bloomberg's Sam Fazeli joins to discuss with Paul Sweeney and Scarlet Fu. (Source: Bloomberg)